CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 147 enrolled
Drug / intervention
escitalopram +1 moredrug
Likely dose
escitalopram 10mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00475878
NCT00475878Phase 3Completed
CompareCT.gov

Antidepressants During Office-Based Buprenorphine

Butler Hospital·interventional·Posted May 21, 2007·Updated Apr 3, 2012

In Brief

A Phase 3 clinical trial evaluating escitalopram and placebo for Opiate Dependence and Depression. Completed, enrolled 147 participants across 1 site.

Detailed Summary

This study is designed to test whether treatment of depressive symptoms using escitalopram improves adherence to Buprenorphine and reduces symptoms of depression for individuals receiving Buprenorphine through their medical provider.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOpiate Dependence, Depression
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMay 21, 2007
Enrollment StartDec 1, 2006
Primary CompletionSep 1, 2009
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 19.1 years ago

Interventions

escitalopramdrug

10mg escitalopram/day for 3 months

placebodrug

placebo capsule/day for 3 months